Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies

被引:69
|
作者
Park, Hwan-Woo [1 ,2 ]
Lee, Jun Hee [2 ]
机构
[1] Konyang Univ, Coll Med, Dept Cell Biol, Taejon, South Korea
[2] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA
关键词
autophagic flux; calcium channel blocker; high fat diet; lipotoxicity; NAFLD; obesity; protein inclusions; verapamil;
D O I
10.4161/15548627.2014.984268
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Nonalcoholic fatty liver disease (NAFLD), typically associated with overnutrition and obesity, is one of the most common liver diseases both in the US and worldwide. During obesity and NAFLD, lipotoxic injuries to hepatocytes can provoke formation of protein inclusions consisting of SQSTM1/p62 and ubiquitinated proteins. It has been suggested that autophagy deregulation during obesity contributes to protein inclusion formation and progression of other liver pathologies including insulin resistance, steatohepatitis, and hepatocellular carcinoma. To examine how lipotoxicity and obesity affect autophagy, we established an in vitro system where cultured HepG2 cells exhibit prominent accumulation of SQSTM1 and ubiquitinated proteins in insoluble inclusion bodies upon treatment with saturated fatty acids. Using this system and a mouse model of obesity, we have determined that obesity induces chronic elevation of cytosolic calcium levels in hepatocytes, which interferes with the fusion between autophagosomes and lysosomes. Intriguingly, pharmacological inhibition of calcium channels using the FDA-approved drug verapamil successfully restores autophagic flux and suppresses protein inclusions, not only in HepG2 cells but also in mouse liver. Verapamil also reduces hepatic lipid droplet accumulation, insulin resistance and steatohepatitis, suggesting that calcium channel blockers can be used for correction of general NAFLD pathologies. Indeed, there have been a number of clinical observations in which beneficial effects of calcium channel blockers against obesity-associated metabolic pathologies are observed in humans and animal models.
引用
收藏
页码:2385 / +
页数:2
相关论文
共 50 条
  • [31] METABOLOMICS REVEALS THAT ALTERATIONS IN CIRCULATING A-KETOGLUTARATE MAY BE RELEVANT IN THE ASSESSMENT OF MORBID OBESITY-ASSOCIATED NONALCOHOLIC FATTY LIVER DISEASE
    Rodriguez-Gallego, E.
    Fernandez-Arroyo, S.
    Riera-Borrull, M.
    Hernandez-Aguilera, A.
    Guirro, M.
    Marine-Casado, R.
    Luciano-Mateo, F.
    Garcia-Heredia, A.
    Marti-Lindez, A. A.
    Beltran-Debon, R.
    Joven, J.
    ATHEROSCLEROSIS, 2014, 235 (02) : E65 - E65
  • [32] NLRP3 inflammasome as a mediator of inflammation and extracellular matrix remodelling in obesity-associated non-alcoholic fatty liver disease
    Unamuno, X.
    Gomez-Ambrosi, J.
    Ramirez, B.
    Rodriguez, A.
    Becerril, S.
    Valenti, V.
    Moncada, R.
    Silva, C.
    Fruhbeck, G.
    Catalan, V.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2020, 50 : 13 - 14
  • [33] Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice
    Petra Mulder
    Martine C. Morrison
    Lars Verschuren
    Wen Liang
    J. Hajo van Bockel
    Teake Kooistra
    Peter Y. Wielinga
    Robert Kleemann
    Scientific Reports, 6
  • [34] Bitter Melon Powder Protects against Obesity-associated Fatty Liver Disease by Improving Colonic Microenvironment in Rats with High-fat Diet-induced Obesity
    Bai Juan
    Zhu Ying
    Dong Ying
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2017, 30 (08) : 610 - +
  • [35] Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice
    Mulder, Petra
    Morrison, Martine C.
    Verschuren, Lars
    Liang, Wen
    van Bockel, J. Hajo
    Kooistra, Teake
    Wielinga, Peter Y.
    Kleemann, Robert
    SCIENTIFIC REPORTS, 2016, 6
  • [36] Bitter Melon Powder Protects against Obesity-associated Fatty Liver Disease by Improving Colonic Microenvironment in Rats with High-fat Diet-induced Obesity
    BAI Juan
    ZHU Ying
    DONG Ying
    BiomedicalandEnvironmentalSciences, 2017, 30 (08) : 611 - 615
  • [37] Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma:Current knowledge and potential for therapeutics
    Imaad Said
    Hassan Ahad
    Adnan Said
    World Journal of Gastrointestinal Oncology, 2022, (05) : 947 - 958
  • [38] Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics
    Said, Imaad
    Ahad, Hassan
    Said, Adnan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (05) : 947 - 958
  • [39] In silico profiling of nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on the treatment of non-alcoholic fatty liver disease
    Patnaik, Damini
    Jena, Atala Bihari
    Kerry, Rout George
    Duttaroy, Asim K.
    LIPIDS IN HEALTH AND DISEASE, 2023, 22 (01)
  • [40] In silico profiling of nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on the treatment of non-alcoholic fatty liver disease
    Damini Patnaik
    Atala Bihari Jena
    Rout George Kerry
    Asim K. Duttaroy
    Lipids in Health and Disease, 22